An overview of ASO-based RNA modulation, AAV-mediated gene supplementation, and CRISPR-based editing as candidate therapeutic platforms for CLTC-ID — with current readiness assessment for each approach.
| Platform | Readiness for CLTC-ID |
|---|---|
| ASO | Highest near-term readiness |
| AAV | Moderate readiness |
| CRISPR | Earliest stage |
| Upregulation | Preclinical — proof-of-concept in SMA |
As of 2025, no CLTC-ID-specific gene therapy or genome-editing trial has been registered in ClinicalTrials.gov or any major international registry. The nearest-term translational path is bespoke ASO design and allele upregulation, modelled on clinically validated approaches in analogous haploinsufficiency syndromes — most notably SCN1A (Dravet syndrome) and STXBP1 encephalopathy — where antisense and upregulation strategies have advanced from preclinical proof-of-concept to early-phase regulatory engagement.[8]
Natural history data are the essential prerequisite for trial readiness: without well-characterised longitudinal outcome measures, it is not possible to power a clinical trial or satisfy regulatory endpoints. Clinicians are encouraged to direct families to natural history registries and to contribute de-identified data where possible.[5]
References
Crooke ST et al. RNA-Targeted Therapeutics. Cell Metab. 2018;27(4):714–39.
Mercuri E et al. Nusinersen versus Sham Control in Later-Onset SMA. NEJM. 2018;378(7):625–35.
Rinaldi C, Wood MJA. Antisense oligonucleotides: next frontier for neurological disorders. Nat Rev Neurol. 2018;14(1):9–21.
Mendell JR et al. Single-Dose Gene-Replacement Therapy for SMA. NEJM. 2017;377(18):1713–22.
Deverman BE et al. Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018;17(9):641–59.
Komor AC et al. Programmable editing of a target base without double-stranded DNA cleavage. Nature. 2016;533(7603):420–4.
Anzalone AV et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–57.
Rangoli A et al. Neuron-targeted gene therapy rescues STXBP1-related disorder phenotypes. Molecular Therapy. Vol 33, Issue 8, 2025, pp 3822–3840.
Spencer M. New Treatment Option (SAT-3247) for DMD Shows Promise. CheckRare. 2025. checkrare.com
Dhillon S. Risdiplam: First Approval. Drugs. 2020;80(17):1853–8. FDA NDA 213535, approved August 2020.